ArticleInternational journal of molecular sciences2022
Biofabrication of Collagen Tissue-Engineered Blood Vessels with Direct Co-Axial Extrusion.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Living Tissues by Design: The Rise of Hybrid Models in Biofabrication.Journal of functional biomaterials · 2026Review
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- Current Status of Bioprinting Using Polymer Hydrogels for the Production of Vascular Grafts.Gels (Basel, Switzerland) · 2024Review
- Construction of vascular grafts based on tissue-engineered scaffolds.Materials today. Bio · 2024Review
- Biological Materials for Tissue-Engineered Vascular Grafts: Overview of Recent Advancements.Biomolecules · 2023Review
- Bioprinting Technologies and Bioinks for Vascular Model Establishment.International journal of molecular sciences · 2023Review
- Vascularization in Bioartificial Parenchymal Tissue: Bioink and Bioprinting Strategies.International journal of molecular sciences · 2022Review
- Tissue-engineered blood vessels for clinical translation: Design logic, representative advances and persistent barriers.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cardiovascular diseases are considered one of the worldwide causes of death, with atherosclerosis being the most predominant. Nowadays, the gold standard treatment is blood vessel replacement by bypass surgery; however, autologous source is not always possible. Thereby, tissue-engineered blood vessels (TEBVs) are emerging as a potential alternative source. In terms of composition, collagen has been selected in many occasions to develop TEBVs as it is one of the main extracellular matrix components of arteries. However, it requires specific support or additional processing to maintain the tubular structure and appropriate mechanical properties. Here, we present a method to develop support-free collagen TEBVs with co-axial extrusion in a one-step procedure with high concentrated collagen. The highest concentration of collagen of 20 mg/mL presented a burst pressure of 619.55 ± 48.77 mmHg, being able to withstand perfusion of 10 dynes/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.